Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : mRNA Based Therapy
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Arcturus Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Achilles and Arcturus Collaborate on Second-Generation mRNA Cancer Vaccines
Details : The collaboration with Arcturus Therapeutics, to evaluate best-in-class, self-amplifying mRNA vaccines for the treatment of patients suffering from neoplasms.
Brand Name : mRNA Based Therapy
Molecule Type : Vaccine
Upfront Cash : Undisclosed
May 22, 2024
Lead Product(s) : mRNA Based Therapy
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Arcturus Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : ATL001,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Achilles Provides Interim Update on Neoantigen T Cells in NSCLC and Melanoma Trials
Details : ATL001 is a clonal neoantigen reactive T cell therapy, which is being evaluated in combination with pembrolizumab for advanced unresectable or metastatic non-small cell lung cancer.
Brand Name : ATL001
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
April 04, 2024
Lead Product(s) : ATL001,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : ATL001,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : cNeT (ATL001) are the active component of the final, precision T cell product which target tumors through recognition of a patient’s clonal neoantigens present on all tumor cells.
Brand Name : cNet
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
November 30, 2022
Lead Product(s) : ATL001,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Autologous T Cell Therapy
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ACE is a proprietary method for determining clonality of patient-specific mutations that drives the PELEUS™ bioinformatics platform. Clonal neoantigens are original mutations formed early in tumor evolution that are expressed on all cancer cells and ab...
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
November 22, 2022
Lead Product(s) : Autologous T Cell Therapy
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : ATL001,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : A positive review by an Independent Data Safety Monitoring Committee, the Company has initiated enrollment in Cohort B of the THETIS clinical trial to evaluate cNeT I(ATL001) in combination with a PD-1 checkpoint inhibitor for the treatment of metastatic...
Brand Name : cNet
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
May 09, 2022
Lead Product(s) : ATL001,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : ATL001
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Center for Breakthrough Medicines
Deal Size : Undisclosed
Deal Type : Partnership
Details : The second GMP manufacturing site will initially support Achilles’ proprietary VELOS™ manufacturing process with an annual capacity of 200 cNeT (Clonal NeoantigenT-cells) doses at peak production. The Company’s first US GMP manufacturing facility t...
Brand Name : cNet
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
April 12, 2022
Lead Product(s) : ATL001
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Center for Breakthrough Medicines
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Antisense Oligonucleotide
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Secarna Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Secarna will employ its commercially validated discovery and development platform, LNAplus™, to generate ASO candidates against selected targets that potentially play a central role in the ex vivo optimization of personalized T cell therapies being dev...
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
November 10, 2021
Lead Product(s) : Antisense Oligonucleotide
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Secarna Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Neoantigen Reactive T cells
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Achilles uses DNA sequencing data from patients, together with its proprietary PELEUS bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop precision T cell-based product candidates specifically targeting thos...
Brand Name : ATL001
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
October 22, 2021
Lead Product(s) : Neoantigen Reactive T cells
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : ATL001
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The primary objective of the trial is to assess the safety and tolerability of cNeT. Clinical efficacy will be evaluated as a secondary measure.
Brand Name : ATL001
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
July 01, 2021
Lead Product(s) : ATL001
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Neoantigen Reactive T cells
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : J.P. Morgan
Deal Size : $175.5 million
Deal Type : Public Offering
Achilles Therapeutics Announces Closing of $175.5 million Initial Public Offering
Details : Achilles has two ongoing Phase I/IIa trials, including a study of a clonal neoantigen T cell therapy in patients with advanced non-small cell lung cancer, which dosed its first patient in June last year.
Brand Name : ATL001
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
April 06, 2021
Lead Product(s) : Neoantigen Reactive T cells
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : J.P. Morgan
Deal Size : $175.5 million
Deal Type : Public Offering
LOOKING FOR A SUPPLIER?